Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Morena Luigia Rocca, Roberta Venturella, Rita Mocciaro, Annalisa Di Cello, Angela Sacchinelli, Valentina Russo, Simona Trapasso, Fulvio Zullo & Michele Morelli. (2015) Polycystic ovary syndrome: chemical pharmacotherapy. Expert Opinion on Pharmacotherapy 16:9, pages 1369-1393.
Read now
Read now
Chin-Hsiao Tseng, Kuo-Yang Lee & Farn-Hsuan Tseng. (2015) An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. Journal of Environmental Science and Health, Part C 33:1, pages 67-124.
Read now
Read now
Articles from other publishers (32)
Chin-Hsiao Tseng. (2023) Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan. Cancers 15:17, pages 4276.
Crossref
Crossref
Sara Khosropoor, Mohaddeseh Sadat Alavi, Leila Etemad & Ali Roohbakhsh. (2023) Cannabidiol goes nuclear: The role of PPARγ. Phytomedicine 114, pages 154771.
Crossref
Crossref
Chin-Hsiao Tseng. (2023) Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients. Pharmaceuticals 16:5, pages 679.
Crossref
Crossref
Tathagata Pradhan, Ojasvi Gupta, Vivek Kumar, Sristi & Gita Chawla. (2022) A comprehensive review on the antidiabetic attributes of thiazolidine‐4‐ones: Synthetic strategies and structure–activity relationships. Archiv der Pharmazie 356:2.
Crossref
Crossref
Chin-Hsiao Tseng. (2022) Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis. BMC Cancer 22:1.
Crossref
Crossref
Mieczysław Dutka, Rafał Bobiński, Tomasz Francuz, Wojciech Garczorz, Karolina Zimmer, Tomasz Ilczak, Michał Ćwiertnia & Maciej B. Hajduga. (2022) SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives. Cancers 14:23, pages 5811.
Crossref
Crossref
Aswathy R. Devan, Bhagyalakshmi Nair, Ayana R. Kumar & Lekshmi R. Nath. (2021) An insight into the role of telmisartan as PPAR‐γ/α dual activator in the management of nonalcoholic fatty liver disease. Biotechnology and Applied Biochemistry 69:2, pages 461-468.
Crossref
Crossref
Zülal Atlı Şekeroğlu, Vedat Şekeroğlu, Seval Kontaş Yedier, Emre İlkun & Louis S. Liou. (2021)
Increased
DNA
strand breaks and neoplastic transformation in human bladder cells treated with pioglitazone
. Environmental and Molecular Mutagenesis 62:2, pages 143-154.
Crossref
Crossref
E. Ripamonti, L. Azoulay, M. Abrahamowicz, R.W. Platt & S. Suissa. (2019) A systematic review of observational studies of the association between pioglitazone use and bladder cancer. Diabetic Medicine 36:1, pages 22-35.
Crossref
Crossref
Angelo Cignarelli, Valentina Annamaria Genchi, Irene Caruso, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola & Francesco Giorgino. (2018) Diabetes and cancer: Pathophysiological fundamentals of a ‘dangerous affair’. Diabetes Research and Clinical Practice 143, pages 378-388.
Crossref
Crossref
Jiten Vora, Kausik Ray, Mikhail Kosiborod, Neil R. Poulter, Sanjay Rajagopalan & Lawrence A. Leiter. (2017) Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment – a clinical appraisal. Journal of Diabetes and its Complications 31:9, pages 1451-1457.
Crossref
Crossref
Tsuyoshi Takiuchi, Hiroko Machida, Marianne S. Hom, Sayedamin Mostofizadeh, Marina Frimer, Laurie L. Brunette & Koji Matsuo. (2017) Association of Metformin Use and Survival Outcome in Women With Cervical Cancer. International Journal of Gynecological Cancer, pages 1.
Crossref
Crossref
Chin-Hsiao Tseng. (2016) Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes. Oncotarget 8:12, pages 19057-19064.
Crossref
Crossref
Chin-Hsiao Tseng. (2016) Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus. Oncotarget 8:2, pages 3042-3048.
Crossref
Crossref
Yadan Chen, Haiming Ma, Dasheng Zhu, Guowei Zhao, Lili Wang, Xiujuan Fu & Wei Chen. (2017) Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets. PPAR Research 2017, pages 1-13.
Crossref
Crossref
Chin-Hsiao Tseng. (2016) Factors Associated with Cancer- and Non-Cancer-Related Deaths among Taiwanese Patients with Diabetes after 17 Years of Follow-Up. PLOS ONE 11:12, pages e0147916.
Crossref
Crossref
Chin-Hsiao Tseng. (2016) Metformin use and cervical cancer risk in female patients with type 2 diabetes. Oncotarget 7:37, pages 59548-59555.
Crossref
Crossref
Chin-Hsiao Tseng. (2016) Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging 8:8, pages 1636-1649.
Crossref
Crossref
Janicélle Fernandes Morais, Juliane Rocha de Sant’Anna, Tais Susane Pereira, Claudinéia Conationi da Silva Franco, Paulo Cezar de Freitas Mathias & Marialba Avezum Alves de Castro-Prado. (2016)
Genotoxic investigation of a thiazolidinedione PPARγ agonist using the
in vitro
micronucleus test and the
in vivo
homozygotization assay
. Mutagenesis 31:4, pages 417-424.
Crossref
Crossref
Durgaprasad M. Kabade, Anand Koppad, Ameet Khatawkar, Savitri D Kabade & Afaq Ahmed. (2016) ORAL HYPOGLYCAEMIC AGENTS IN THE MANAGEMENT OF TYPE II DIABETES MELLITUS. Journal of Evidence Based Medicine and Healthcare 3:45, pages 2272-2282.
Crossref
Crossref
Rashid K. Sayyid & Neil E. Fleshner. (2016) Diabetes Mellitus Type 2: A Driving Force for Urological Complications. Trends in Endocrinology & Metabolism 27:5, pages 249-261.
Crossref
Crossref
N. Sch?ffel, S. S. Scholz, M. H. K. Bendels, M. Bundschuh & D. A. Groneberg. (2016) HarnblasenkrebsBladder cancer. Zentralblatt f?r Arbeitsmedizin, Arbeitsschutz und Ergonomie 66:3, pages 167-170.
Crossref
Crossref
Chin‐Hsiao Tseng. (2015) Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. European Journal of Clinical Investigation 46:1, pages 70-79.
Crossref
Crossref
Chin-Hsiao Tseng. (2016) Use of metformin and risk of kidney cancer in patients with type 2 diabetes. European Journal of Cancer 52, pages 19-25.
Crossref
Crossref
Chin-Hsiao Tseng. (2015) Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese. BMC Cancer 15:1.
Crossref
Crossref
Chin-Hsiao Tseng. (2015) Type 2 Diabetes Mellitus and Kidney Cancer Risk: A Retrospective Cohort Analysis of the National Health Insurance. PLOS ONE 10:11, pages e0142480.
Crossref
Crossref
Daniel Levin, Samira Bell, Reijo Sund, Sirpa A. Hartikainen, Jaakko Tuomilehto, Eero Pukkala, Ilmo Keskim?ki, Ellena Badrick, Andrew G. Renehan, Iain E. Buchan, Samantha L. Bowker, Jasjeet K. Minhas-Sandhu, Zafar Zafari, Carlo Marra, Jeffrey A. Johnson, Bruno H. Stricker, Andr? G. Uitterlinden, Albert Hofman, Rikje Ruiter, Catherine E. de Keyser, Thomas M. MacDonald, Sarah H. Wild, Paul M. McKeigue & Helen M. Colhoun. (2014) Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58:3, pages 493-504.
Crossref
Crossref
Chin-Hsiao Tseng. (2015) Use of Insulin and Mortality from Breast Cancer among Taiwanese Women with Diabetes. Journal of Diabetes Research 2015, pages 1-8.
Crossref
Crossref
Chin-Hsiao Tseng. (2014) Metformin Reduces Thyroid Cancer Risk in Taiwanese Patients with Type 2 Diabetes. PLoS ONE 9:10, pages e109852.
Crossref
Crossref
Chin-Hsiao Tseng. (2014) Pioglitazone and thyroid cancer risk in Taiwanese patients with type 2 diabetes 台湾2型糖尿病患者使用吡格列酮与甲状腺癌风险. Journal of Diabetes 6:5, pages 448-450.
Crossref
Crossref
Chin-Hsiao Tseng. (2014) Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes. Metabolism 63:8, pages 1049-1055.
Crossref
Crossref
Hao-Wen Lin & Chin-Hsiao Tseng. (2014) A Review on the Relationship between SGLT2 Inhibitors and Cancer. International Journal of Endocrinology 2014, pages 1-6.
Crossref
Crossref